David L. Lahr

Io Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index4.5kcitations74works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chromatin Remodeling and Cancer(40), Protein Degradation and Inhibitors(17), Gas Sensing Nanomaterials and Sensors(9), Computational Drug Discovery Methods(6), Bioinformatics and Genomic Networks(6)

Publications74 total

Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025· 1 citedOpen Access
Author response: Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies
Blood·2025
Author response: Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Structural and functional basis of PU.1-BAF interaction enables targeting of lineage-specific transcription
2025· 1 cited
Data from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Figure 11 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Table 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Figure 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Data 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Figure 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Table 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Figure 4 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Table 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
Supplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
2025Open Access
page 1 of 4Next →

Frequent Co-authors

Martin Hentemann(21), GiNell Elliott(20), Gabriel J. Sandoval(13), Ammar Adam(13), Steven F. Bellon(13), Alexis Khalil(13), Jessica Piel(13), Kim Horrigan(12), Gromoslaw A. Smolen(12), Courtney D. DiNardo(11), Amir T. Fathi(11), Ashwin Kishtagari(11), Kapil N. Bhalla(11), Alfonso Quintás‐Cardama(11), Sarah A. Reilly(11), Caroline Almon(11), Caitlin Patriquin(11), Salah Nabhan(11), Kathleen Healy(11), Denice Hickman(11)